AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
AVB
ACCE-researched

AvalonBay Communities Inc. Common Stock (AVB) fair value

Real Estate · REIT - Residential · NYSE · United States
$184.06+0.00%
Market cap $26.3BNext earnings 2026-10-28Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 20% above our fair value
Price
$184.06
Model fair valueConfidence: good
$153
Model range
$72.83 to $245
Fair value $153
Price $184
3 models fit AvalonBay Communities Inc. Common Stock and they disagree: 1 of 3 land within 15% of the average.
Two or more of our models back this value.
Premium(i)Silver66
Valued as a REIT (property company): Price to FFO, Dividend discount, and EV/EBITDA comparison.
ACCE opinionAvalonBay Communities Inc. Common Stock (AVB)
Fair value (3 models)
$153
ACCE price target
$189
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 18:04 CEST; previously $133 since 11 Oct 2026, 00:00 CEST.
ACCE price target published on 18 Oct 2026, 00:00 CEST; previously $175 since 12 May 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 18:04 CEST.
Price used: $184 at the close on 25 Aug 2026, 22:00 CEST.
Models: EV/EBITDA comparison, Dividend discount, and Price to FFO.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
20.1% above
-16.7% to fair value
ACCE score
48
out of 100
Analysts
42% buy
24 covering
P/E
25.2x
forward 15.1x
1-year return
-4.3%
Dividend yield
3.84%

AvalonBay Communities Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

AvalonBay owns and operates apartment communities in high-barrier coastal markets, along with a smaller development pipeline, and it is one of the larger residential REITs by market value at about $26.3B. Its moat rests on land scarcity and entitlement difficulty in places like the Northeast, Mid-Atlantic and parts of California, where new supply is slow to arrive and rents tend to hold up through cycles. The near-term question is whether revenue growth of 2.3% can reaccelerate as development deliveries lease up. The stock screens expensive on trailing earnings at 25.2x but cheaper on forward estimates at 15.1x, so the case depends on whether that gap closes through earnings delivery rather than multiple expansion. A 30.6% operating margin and 8.5% ROE are solid for a levered REIT, though the composite score of 48/100 and the absence of index membership suggest the market is not yet paying up for the story, which makes it worth a deeper look on the earnings bridge.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • high
    Earnings collapse
    YoY earnings down 41.3% while revenue up only 2.3%. Operating leverage reversed sharply; net margin at 33.3% masks underlying deterioration in earnings power.
  • high
    Valuation disconnect
    Forward P/E 36.8 vs current 25.2 signals market expects further earnings pressure.
  • moderate
    Score deterioration
    ACCE score fell 9 points in 90 days (59 to 50). Growth score collapsed to 19/100, signalling deceleration concerns despite 5.5% five-year revenue CAGR.

AI research notes

AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Aug 25, 2026
Why it could do well
  • Strong free cash flow of $1.4B supports a 5.4% yield, well above risk-free rates.
  • Net margin of 33.3% and five-year revenue growth of 5.5% show pricing power and scale.
  • Analyst mean target of $201.71 implies 9.6% upside from current price of $184.06.
Why it could disappoint
  • Forward P/E of 36.8x versus trailing 25.2x signals consensus expects earnings to fall.
  • ROIC of 4.1% and ROE of 8.5% lag cost of capital, destroying shareholder value.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 28, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where AVB's valuation models land
Price
$184.06
Model fair value
$153
Model range
$72.83 to $245
Fair value $153
Price $184
The price sits inside the model range.
Model
Fair value
Upside
Dividend discount
EV/EBITDA comparison
Price to FFO
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Mixed42% buy · 24 covering analysts
● Strong buy 5● Buy 5● Hold 14● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+187.5%
1 month
+171.1%
3 months
-1.2%
6 months
+2.4%
YTD
+1.5%
1 year
-4.3%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
19 Oct 2026, 18:04 CESTRatingOvervaluedfirst publication$184
19 Oct 2026, 18:04 CESTFair value$153$133$184
18 Oct 2026, 00:00 CESTACCE price target$189$175$184
11 Oct 2026, 00:00 CESTFair value$133$108$184
21 Sept 2026, 00:00 CESTFair value$108$109$184
16 Sept 2026, 00:00 CESTFair value$109$113$184
14 Sept 2026, 00:00 CESTFair value$113$115$184
5 Sept 2026, 00:00 CESTFair value$115$116$184
28 Aug 2026, 00:00 CESTFair value$116$114$184
26 Aug 2026, 00:00 CESTFair value$114$116$184

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full AVB page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth19Value-Quality76Momentum-Total48
Valuation
Trailing P/E
25.2x
Forward P/E
15.1x
PEG
6.97
P/B
2.22x
EV / Revenue
11.6x
Book value/sh
$84.85
Enterprise value
$35.8B
Profitability
ROE
8.5%
FCF yield
5.38%
ROIC
4.1%
Health and risk
Debt / equity
0.80
Dividend yield
3.84%
Beta
0.77

Price

-2.8% · 1Y

Ask anything about AVB

Answered from AvalonBay Communities Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x25.2xhigh 91.1x
ROEbetter than 83% of peers
low 0%8%high 12%
Div yieldbetter than 33% of peers
low 3.7%3.8%high 12.6%

Peers

Prices Aug 25, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
AVB AvalonBay Communities Inc. Common Stock$184.06$15320% above25.2x8.5%7648
EQR Equity Residential Common Shares of Beneficial Interest$63.66$5320% above28.7x8.0%8150
SOJC Southern Company (The) Series 2017B 5.25% Junior Subordinated Notes due December 1 2077$18.28--21.8x0.0%1918
ESS Essex Property Trust Inc. Common Stock$282.45$21730% above43.3x7.7%7652
INVH Invitation Homes Inc. Common Stock$27.53$1854% above24.6x7.0%7263
PRS Prudential Financial Inc. 5.625% Junior Subordinated Notes due 2058$19.63$203% below-11.8%3826
SUI Sun Communities Inc. Common Stock$119.86$9723% above91.1x1.7%5938

Sector report card

Where AVB ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 12, 2026
    ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
  • GlobeNewswire•Oct 6, 2026
    ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
  • GlobeNewswire•Aug 12, 2026
    ArriVent BioPharma Reports Second Quarter 2026 Financial Results
4 more press releases · full archive on Investor+.INVESTOR
40 filings
August 2026
Aug 17
8-KCurrent reportPeriod 2026-08-17
View on SEC →
Aug 17
Form 4Insider transactionPeriod 2026-08-17
View on SEC →
Aug 17
Form 4Insider transactionPeriod 2026-08-17
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR